Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

RF GP Ablation Added to PEF PVI for Paroxysmal AF (REGATTA-AF)

11 de noviembre de 2026 actualizado por: Predrag Stojadinovic, Institute for Clinical and Experimental Medicine

RadiofrEquency Ablation of Ganglionated Plexi Added to The Pulsed ElecTric Field Pulmonary Vein Isolation for PAroxysmal Atrial Fibrillation (REGATTA-AF Study)

This study will investigate whether adjunctive RF GP ablation, when added to PF PVI, improves freedom from AF or atrial tachycardia (AT). By directly addressing the potential limitation of autonomic modulation associated with PF ablation alone, this study will provide mechanistic and clinically relevant insights into the role of parasympathetic modulation of the heart in preventing AF recurrence.

The results are expected to yield novel, clinically meaningful evidence that may help refine and optimize catheter ablation workflows, particularly in the era of non-thermal energy sources.

Descripción general del estudio

Descripción detallada

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and pulmonary vein isolation (PVI) represents the cornerstone therapeutic strategy in patients with symptomatic paroxysmal AF. Pulsed electric field (PEF) ablation is a novel energy source that enables safe and durable PVI but has a limited and only transient effect on the autonomic nervous system, which plays an important role in the pathogenesis of AF. Previous studies have shown that modification of ganglionated plexi (GP) using radiofrequency (RF) energy may result in more effective and sustained parasympathetic atrial denervation, thereby potentially improving long-term ablation outcomes.

The aim of this project is to compare the efficacy of PEF PVI alone versus a combined strategy of PEF PVI plus adjunctive RF GP ablation in patients with antiarrhythmic drug-refractory paroxysmal AF. This is a multicentre, randomized, single-blind superiority trial. A total of 250 patients will be enrolled across three highly specialized centres in the Czech Republic. The primary endpoint is freedom from recurrent AF/atrial tachycardia lasting >30 seconds during 12 months of follow-up (excluding a 2-month blanking period) without the use of Class I/III antiarrhythmic drugs. Secondary endpoints include arrhythmia burden assessed by long-term ECG monitoring, quality of life, procedural safety, and detailed evaluation of cardiac autonomic function using both invasive and non-invasive methods.

The project will provide the first direct clinical evidence on the benefit of targeted autonomic modulation added to PEF PVI. The results may substantially influence the optimization of ablation strategies in paroxysmal AF and contribute to the refinement of future clinical guidelines.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

250

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Prague
      • Prague, Prague, Chequia, 14200
        • Institute for Clinical and Experimental Medicine

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

30 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Patients with drug-resistant symptomatic paroxysmal AF meeting all the following criteria:

    1. Paroxysmal AF that terminates spontaneously or with intervention within 7 days of onset.
    2. Failed AAD treatment, defined as ineffective, intolerant or inappropriate ≥1 Class I-IV AAD.
  2. Patients who are ≥30 and ≤65 years of age on the day of enrolment.

  3. Patients who are willing and capable of:

    1. Providing informed consent to undergo study procedures AND
    2. Participating in all examinations, follow-up visits, and tests associated with this clinical study.
  4. Effective contraception for women of childbearing potential.

  5. Effective oral anticoagulation for >3 weeks before the planned ablation procedure.

Exclusion Criteria:

  1. Persistent, long-standing persistent, or permanent AF.
  2. AF secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes.
  3. Left atrial (LA) anteroposterior diameter ≥50 mm (by transthoracic echocardiography).
  4. Left ventricular ejection fraction <40%.
  5. Autonomic dysfunction, e.g., cardiac autonomic neuropathy due to diabetes mellitus.
  6. Any prior atrial endocardial or epicardial ablation procedure, including cavotricuspid isthmus (CTI) ablation or right-sided AT.
  7. Any prior atrial surgery.
  8. Intra-atrial septal patch or interatrial shunt.
  9. General contraindications of catheter ablation
  10. LA appendage closure, device, or occlusion, past or anticipated.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: RF GP + PEF PVI

Radiofrequency ablation of ganglionated plexi added to pulmonary vein isolation and roof line ablation using pulsed electric field

isolation of pulmonary veins and roof line ablation using pulsed electric energy

ablation of GP using radiofrequency energy

Comparador activo: PEF PVI

Pulmonary vein isolation and roof line ablation using pulsed electric field energy

isolation of pulmonary veins and roof line ablation using pulsed electric energy

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Freedom from recurrent AF/AT >30 s during the first 12 months
Periodo de tiempo: From the ablation procedure through the 12-month follow-up.

The primary outcome of the study is freedom from recurrent AF/AT >30 s during the first 12 months (excluding a 2-month blanking period) after the procedure without the use of Class I or III AADs.

From the ablation procedure through the 12-month follow-up.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Quality of life
Periodo de tiempo: Baseline and at the 12-month visit.

This measure will be assessed by the AFEQT questionnaire. A higher score = a better quality of life (0 = worst possible quality of life, 50 = intermediate impairment, and 100 = best possible quality of life).

Baseline and at the 12-month visit.
Periprocedural complications, MACE
Periodo de tiempo: From the ablation procedure through the 12-month follow-up.

periprocedural complications, including cardiac tamponade, stroke/TIA, major bleeding requiring intervention or transfusion, vascular access complications requiring treatment; major adverse cardiac events during follow-up

From the ablation procedure through the 12-month follow-up.
Acute vagal denervation assessed by ECVS
Periodo de tiempo: Periprocedural

ECVS will be performed during the ablation procedure at baseline and 20 minutes after the last PF of RF application. The longest P-P and R-R pauses ( in seconds) during ECVS will be recorded.

Periprocedural
Long-term cardiac vagal denervation
Periodo de tiempo: Baseline and at the 12-month visit.

Patients will undergo atropine testing consisting of an intravenous bolus of atropine sulfate. ECG will be recorded immediately before and 5 minutes after the injection.

Baseline and at the 12-month visit.
Vagal atrial induction test (VAFIT)
Periodo de tiempo: Periprocedural

This test will be performed to assess the inducibility of AF/AF at baseline and at the end of the procedure. The induction protocol will use programmed atrial stimulation (a short train of 4 cycles at 120 bpm followed by one extrastimulus) from the low lateral right atrium, synchronised with the ECVS.

Periprocedural

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de abril de 2027

Finalización primaria (Estimado)

1 de abril de 2028

Finalización del estudio (Estimado)

1 de abril de 2029

Fechas de registro del estudio

Enviado por primera vez

14 de marzo de 2026

Primero enviado que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir